Medvet licenses cell line for cancer antibody
South Australia’s Medvet Science has licensed a cell line from ACYTE Biotech to produce its monoclonal cancer antibody APOMAB.
Medvet has arranged to use ACYTE’s XL-99 Chinese hamster ovary cell line to produce APOMAB in the quantities potentially required for clinical applications.
Medvet is producing the antibody for the diagnosis and treatment of cancers. Its target is La/SSB, an essential ribonucleoprotein component found in all cancers.
XL-99 is a fully characterised, cGMP banked, CHO-K1 parental cell line capable of producing monoclonal antibodies at high yields and cell density.
Medvet is currently undertaking clinical proof-of-concept development of APOMAB at the Royal Adelaide Hospital. The hospital’s head of cancer clinical trials, Professor Michael Brown, is guiding the development.
Medvet’s sole shareholder is the Central Adelaide Local Health Network (CALHN), a division of the government department SA Health.
“For clinical efficacy studies of APOMAB, and potential commercial production, we require a cell line capable of producing clinically viable amounts of the antibody, with high cell density at low cost of goods,” Brown commented.
“Our ongoing work with ACYTE indicates that XL-99 will achieve these aims and provide a productive cell line which can be easily transferred to our CMOs.”
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
